Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Isaiah Brown

Vascular Surgery Sun City, AZ Medical Doctor

NPI 1003235102 CMS profile 8801722

9744 W. Bell Rd, Suite A, Sun City, AZ 85351

Open in the dashboard

General payments

$21,542

129 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Isaiah Brown of Sun City, AZ is reported in the CMS Open Payments database as having received $21,542 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,499 42
2024 General $4,172 30
2023 General $1,832 38
2022 General $1,399 13
2021 General $372 3
2020 General $10,269 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Isaiah Brown
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Isaiah Brown were reported at $3,499. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Isaiah Brown Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $10,269 $348 $118–$1,110 $114
2021 $372 $471 $158–$1,421 $132
2022 $1,399 $725 $222–$2,183 $149
2023 $1,832 $836 $257–$2,440 $160
2024 $4,172 $909 $252–$2,619 $164
2025 $3,499 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic Vascular, Inc. $10,269 3 payments
  2. AngioDynamics, Inc. $3,394 37 payments
  3. Penumbra, Inc. $2,711 15 payments
  4. Endologix, Inc. $2,054 29 payments
  5. Medtronic, Inc. $1,521 15 payments
  6. W. L. Gore & Associates, Inc. $771 9 payments
  7. Inari Medical, Inc. $255 4 payments
  8. Bolton Medical Inc $222 5 payments
  9. Cook Medical LLC $85 1 payment
  10. Boston Scientific Corporation $85 3 payments
  11. Other $176 8 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $10,000 1 payment
  2. Food and Beverage $6,542 118 payments
  3. Travel and Lodging $2,315 7 payments
  4. Long term medical supply or device loan $2,278 1 payment
  5. Education $407 2 payments
Products named General payments · program years 2020–2025
  1. Endurant $10,000 1 payment
  2. Indigo System $2,376 9 payments
  3. Auryon Laser System 100-120 Vac Et $2,278 1 payment
  4. AURYON LASER SYSTEM 100-120 VAC Pad $1,117 36 payments
  5. Alto Abdominal Stent Graft System $1,097 15 payments
  6. PIVOX Oblique Lateral Spinal System $854 4 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $547 6 payments
  8. AFX2 Bifurcated Endograft System $503 12 payments
  9. ENDOCROSS Device $454 2 payments
  10. Torus Stent Graft System $454 2 payments
  11. Other $2,235 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

74

Median for Vascular Surgery: 122

Drug cost

$11,144

Median for Vascular Surgery: $14,135

Branded share of claims

52.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $10,282
Cilostazol Generic 12 $427
Clopidogrel Clopidogrel Bisulfate Brand 28 $319
Oxycodone Hcl Generic 23 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$167,057

Medicare's payments for the services billed

Medicare patients

267

Average age 74

Services billed

868

133 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 62%
Diabetes 56%
Arthritis 52%
Ischemic heart disease 50%
COPD 37%
Heart failure 36%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record